Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06567743 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
A Phase 2 study of High-Risk Non-Muscle-Invasive Bladder Cancer, sponsored by CG Oncology.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 325
- Enrollment target
- 20
- Study locations
NCT06567743: Recruiting Phase 2 study of High-Risk Non-Muscle-Invasive Bladder Cancer, sponsored by CG Oncology.
NCT06567743 is a Phase 2 study of High-Risk Non-Muscle-Invasive Bladder Cancer that is actively recruiting participants, run by CG Oncology. The registered enrollment target is 325 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (144% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06567743, a Phase 2 study of High-Risk Non-Muscle-Invasive Bladder Cancer, is actively recruiting participants, sponsored by CG Oncology.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 325 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Primary Outcome
Determine the complete response rate at any time following treatment with cretostimogene in participants with BCG-naïve CIS with or without concomitant high-grade Ta or T1 disease at baseline
Conditions Studied
Interventions
- DRUG Cretostimogene Grenadenorepvec
Study Locations (20)
California
- Michael G Oefelein, MD Clinical Trials - Bakersfield
- Genesis Research (Greater Los Angeles) - Los Alamitos
- Advanced Urology - Los Angeles
- Urology Center of Southern California - Murrieta
- University of California, Irvine - Orange
- Om research - San Diego
- University of Southern California - San Diego
- Genesis Research (Greater Los Angeles) - Torrance
Florida
- University of Florida - Gainesville
- Mayo Clinic Florida - Jacksonville
- Advanced Urology Institute (Solaris) - Largo
- Advanced Urology Institute - Oxford
- Advanced Urology Institute - Tallahassee (Solaris) - Tallahassee
Arizona
- Mayo Clinic Arizona - Phoenix
- Arizona Urology Specialty - Tucson
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
- Arkansas Urology - Little Rock
Colorado
- Colorado Urology - Lakewood
- Urology Associates, Lone Tree - Lone Tree
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 2 |
What NCT06567743 shows while recruiting
NCT06567743 is an interventional study that assigns participants to a tested intervention. The registered 325 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (144% higher).
The record links to 1 condition, with High-Risk Non-Muscle-Invasive Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cretostimogene Grenadenorepvec is the first listed.
NCT06567743 names 20 study sites across 6 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06567743 about?
NCT06567743 is a clinical study titled "Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC". This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
What is the current status of trial NCT06567743?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 325 participants. The study started on 2024-09-16. Estimated completion is 2027-12-30.
What conditions does trial NCT06567743 study?
This clinical trial studies the following conditions: High-Risk Non-Muscle-Invasive Bladder Cancer.
What interventions are being tested in trial NCT06567743?
The interventions under investigation include: Cretostimogene Grenadenorepvec (DRUG).
Who is sponsoring clinical trial NCT06567743?
This trial is sponsored by CG Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06567743 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High-Risk Non-Muscle-Invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06567743's enrollment target sits among peer trials
325 148th of 2000 higher than 1,852 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02543983 · 325 participants · Phase 2
Neurobiology of Suicide
- NCT03016819 · 325 participants · Phase 3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- NCT03288207 · 325 participants · NA
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
- NCT04986657 · 325 participants · NA
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI